Safety and efficacy of rimegepant orally disintegrating tablet for the acute treatment of migraine in China and South Korea: a phase 3, double-blind, randomised, placebo-controlled trial

医学 偏头痛 安慰剂 双盲 临床试验 传统医学 内科学 药理学 替代医学 病理
作者
Shengyuan Yu,Byung‐Kun Kim,Aihong Guo,Manho Kim,Mingjie Zhang,Zhen Wang,Jianguang Liu,Heui‐Soo Moon,Ge Tan,Qian Yang,Donnie McGrath,Michael Hanna,David Stock,Gao Yanfei,Robert Croop,Zhihong Lu
出处
期刊:Lancet Neurology [Elsevier BV]
卷期号:22 (6): 476-484 被引量:24
标识
DOI:10.1016/s1474-4422(23)00126-6
摘要

No acute treatments targeting calcitonin gene-related peptide (CGRP) have been approved for use in China or South Korea. We aimed to compare the efficacy and safety of rimegepant-an orally administered small molecule CGRP antagonist-with placebo in the acute treatment of migraine among adults in these countries.This double-blind, randomised, placebo-controlled, multicentre phase 3 trial was done at 86 outpatient clinics at hospitals and academic medical centres (73 in China and 13 in South Korea). Participants were adults (≥18 years) with at least a 1-year history of migraine who had two to eight moderate or severe attacks per month and fewer than 15 headache days per month within the 3 months before the screening visit. Participants were randomly assigned (1:1) to 75 mg rimegepant or placebo to treat a single migraine attack of moderate or severe pain intensity. Randomisation was stratified by the use of preventive medication and by country. The allocation sequence was generated and implemented by study personnel using an interactive web-response system accessed online from each study centre. All participants, investigators, and the sponsor were masked to treatment assignment. The coprimary endpoints of freedom from pain and freedom from the most bothersome symptom (nausea, phonophobia, or photophobia) 2 h after dosing were assessed in the modified intention-to-treat (mITT) population (randomly assigned participants who took study medication for a migraine attack of moderate or severe pain intensity, and provided at least one efficacy datapoint after treatment) using Cochran-Mantel Haenszel tests. Safety was assessed in all participants who received rimegepant or placebo. The study is registered with ClinicalTrials.gov, number NCT04574362, and is completed.1431 participants were randomly assigned (716 [50%] to rimegepant and 715 [50%] to placebo). 668 (93%) participants in the rimegepant group and 674 (94%) participants in the placebo group received treatment. 1340 participants were included in the mITT analysis (666 [93%] in the rimegepant group and 674 [94%] in the placebo group). 2 h after dosing, rimegepant was superior to placebo for pain freedom (132 [20%] of 666 vs 72 [11%] of 674, risk difference 9·2, 95% CI 5·4-13·0; p<0·0001) and freedom from the most bothersome symptom (336 [50%] of 666 participants vs 241 [36%] of 674 participants, 14·8, 9·6-20·0; p<0·0001). The most common (≥1%) adverse events were protein in urine (8 [1%] of 668 participants in the rimepegant group vs 7 [1%] of 674 participants in the placebo group), nausea (7 [1%] of 668 vs 18 [3%] of 674), and urinary tract infection (5 [1%] of 668 vs 8 [1%] of 674). There were no rimegepant-related serious adverse events.Among adults living in China or South Korea, a single dose of 75 mg rimegepant was effective for the acute treatment of migraine. Safety and tolerability were similar to placebo. Our findings suggest that rimegepant might be a useful new addition to the range of medications for the acute treatment of migraine in China and South Korea, but further studies are needed to support long-term efficacy and safety and to compare rimegepant with other medications for the acute treatment of migraine in this population.BioShin Limited.For the Chinese and Korean translations of the abstract see Supplementary Materials section.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
超级灵竹完成签到,获得积分10
1秒前
HuiHui发布了新的文献求助10
2秒前
3秒前
4秒前
香蕉觅云应助科研通管家采纳,获得10
5秒前
5秒前
汉堡包应助科研通管家采纳,获得30
6秒前
6秒前
852应助科研通管家采纳,获得10
6秒前
6秒前
顾矜应助科研通管家采纳,获得10
6秒前
6秒前
斯文败类应助科研通管家采纳,获得10
6秒前
6秒前
6秒前
水木应助科研通管家采纳,获得20
6秒前
大个应助未明的感觉采纳,获得10
8秒前
光亮的半山完成签到,获得积分10
9秒前
9秒前
10秒前
10秒前
slx发布了新的文献求助10
11秒前
Akim应助比利时光采纳,获得10
11秒前
思源应助waitingfor采纳,获得10
12秒前
12秒前
DueR完成签到,获得积分10
13秒前
清爽乐菱应助失眠的夜梦采纳,获得30
13秒前
磊磊完成签到,获得积分10
14秒前
Chelry发布了新的文献求助30
14秒前
闾丘剑封发布了新的文献求助10
14秒前
Chief完成签到,获得积分0
15秒前
mk91发布了新的文献求助10
15秒前
镇江市第一人民医院第一深情完成签到,获得积分10
16秒前
xiaoyuanbao1988完成签到,获得积分10
16秒前
qin希望应助不回首采纳,获得10
17秒前
上官若男应助不回首采纳,获得10
17秒前
科研通AI2S应助不回首采纳,获得10
17秒前
Jasper应助不回首采纳,获得10
17秒前
科研通AI5应助不回首采纳,获得10
17秒前
JamesPei应助不回首采纳,获得10
17秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989510
求助须知:如何正确求助?哪些是违规求助? 3531756
关于积分的说明 11254536
捐赠科研通 3270255
什么是DOI,文献DOI怎么找? 1804947
邀请新用户注册赠送积分活动 882113
科研通“疑难数据库(出版商)”最低求助积分说明 809176